Ipilimumab NEW
| Price | $455 | $585 | $786 |
| Package | 1mg | 2mg | 5mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-01 |
Product Details
| Product Name: Ipilimumab | CAS No.: 477202-00-9 |
| Purity: 98.50% | Supply Ability: 10g |
| Release date: 2026/06/01 |
Product Introduction
Bioactivity
| Name | Ipilimumab |
| Description | Ipilimumab (Yervoy) is an antibody inhibitor that blocks the inhibitory receptor cytotoxic T-lymphocyte antigen-4 (CTLA-4) on T cells, with immune-activating properties. Used for the treatment of unresectable or metastatic melanoma, this antibody exhibits antitumor activity. |
| Cell Research | Objective: Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. Concentrations: 0, 0.5, 5.0, and 50 μg/mL. Incubation Time: 10-14 days. Method: hPBMC were stimulated with anti-CD3 monoclonal antibody with or without ipilimumab and expanded for 10-14 days. ATC were harvested and armed with anti-CD3 x anti-EGFR BiAb (EGFRBi) or anti-CD3 x anti-CD20 BiAb (CD20Bi) to test for redirected cytotoxicity against COLO356/FG pancreatic cancer cell line or Burkitt's lymphoma cell line (Daudi). |
| Animal Research | Objective: To investigate whether Ipilimumab and PD-1 antibody enhance the ability of T cells to control the outgrowth of EBV-induced lymphomas. Formulation: PBS. Dosages: 100 μg, three times weekly |
| In vitro | Methods: In a co-culture system of Jurkat T cells expressing CTLA-4 and Raji B cells, anti-CD3 antibody and gradient concentrations of Ipilimumab (0–100 μg/mL) were added, and luciferase activity driven by the IL-2 promoter was detected after 4 hours of incubation. Results: Ipilimumab concentration-dependently enhanced luciferase expression (up to approximately 3-fold), and replacing with Raji cells highly expressing CD80/CD86 eliminated the early inhibitory effect produced by low concentrations of Ipilimumab. [1] |
| In vivo | Methods: In an hCTLA-4 transgenic mouse MC-38 subcutaneous xenograft tumor model, Ipilimumab was administered by intraperitoneal injection at a dose of 10 mg/kg, twice weekly for 3 consecutive weeks (control group received PBS). Results: The Ipilimumab treatment group showed complete tumor regression in 2 out of 7 mice, comparable to the efficacy of pro-Ipilimumab, confirming its antitumor activity. [2] |
| Storage | Store at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | MDX-010 | MDX010 | MDX 010 | Ipilimumab | Inhibitor | inhibit | CTLA-4 | BMS-734016 | BMS734016 | BMS 734016 |
| Inhibitors Related | Benzyl cinnamate | (9α,13α,14α)-4-Hydroxy-3,7-dimethoxy-7,8-didehydromorphinan-6-one | Pirazolac | Sodium Iodoacetate | Teneligliptin hydrobromide | Soquelitinib | Difenpiramide | Anti-inflammatory agent 36 | MG-T-19 | Anti-inflammatory agent 35 | Isoegomaketone | Complete Freund's adjuvant |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP4Y
|
Dingwang Technology (Wuhan) Co., Ltd.
|
2025-08-22 | ||
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-06-12 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY